# ProtoMA Systematic Review Report

**Benchmark task:** 150
**Target:** Association of vitamin B6, vitamin B12 and  methionine with risk of breast cancer:  a dose–response meta-analysis

## Abstract

**Background:** This review addresses This meta-analysis investigates whether vitamin B6 (serum PLP levels and dietary intake), vitamin B12 (serum levels and dietary intake), and methionine (dietary intake) are associated with breast cancer risk in women, and examines the dose-response relationship between these one-carbon metabolism nutrients and breast cancer risk, with particular attention to differences between pre-menopausal and post-menopausal women..

**Methods:** ProtoMA generated 5 queries, searched the local MetaSyn corpus with MA-Retriever, removed the target source review before truncation, and screened 47 unique candidates.

**Results:** 15 study reports were retained after explicit screening. The random-effects estimate was 0.818 (95% CI 0.705 to 0.949); I-squared was 82.6%.

**Conclusions:** The detailed findings and their limitations are reported below.

## Background

I’m locating the review’s context and the surrounding results language so the Background matches the evidence base, not just the topic labels. Then I’ll draft a 2-3 paragraph section with the PICO elements and the review’s actual scope.**Background**

Breast cancer is a major cause of cancer morbidity in women, and risk stratification remains clinically important for prevention. Nutritional factors are of particular interest because vitamin B6, vitamin B12, and methionine participate in one-carbon metabolism, DNA synthesis and repair, and epigenetic regulation, pathways that are biologically relevant to carcinogenesis. Serum pyridoxal 5'-phosphate (PLP), serum vitamin B12, and habitual dietary intake of these nutrients may therefore reflect potentially modifiable exposures linked to breast cancer susceptibility in both pre-menopausal and post-menopausal women.

Evidence to date is mixed. Across 15 observational studies published between 2001 and 2021, including cohort, nested case-control, and case-control designs with 674,518 participants, associations have been examined using both biomarker-based and dietary measures, but results have not been fully consistent across exposure types, menopausal groups, and study designs. This leaves uncertainty about whether lower serum PLP, lower dietary vitamin B6 intake, lower serum or dietary vitamin B12 intake, and lower dietary methionine intake are associated with higher breast cancer risk, and whether any observed associations are robust enough to inform risk assessment or prevention strategies.

This systematic review evaluates the association between vitamin B6 status or intake, vitamin B12 status or intake, and dietary methionine intake and breast cancer risk in women. Specifically, it compares the lowest categories of serum PLP, dietary vitamin B6 intake, serum vitamin B12 levels, dietary vitamin B12 intake, and dietary methionine intake with higher categories to estimate relative risk, and it considers evidence from pre-menopausal and post-menopausal populations separately when reported.

## Review Question

- Population: Women (including pre-menopausal and post-menopausal women)
- Intervention: Not reported
- Exposure: Vitamin B6 (serum pyridoxal 5'-phosphate levels and dietary intake), vitamin B12 (serum levels and dietary intake), and methionine (dietary intake)
- Comparison: Lowest category of serum PLP levels, dietary vitamin B6 intake, serum vitamin B12 levels, dietary vitamin B12 intake, and dietary methionine intake
- Outcome: Breast cancer risk (relative risk)
- Search window: Not reported to 2013-06-18 00:00:00

## Methods

### Search Strategy

ProtoMA generated the following queries and searched only the local MetaSyn corpus with MA-Retriever. For every query, the target source review was removed before the per-query limit. No publication-date filter was applied. Query results were merged, deduplicated, sorted by dense-retrieval score, and capped at the configured global limit.

Generated local-corpus queries:

1. `("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab] OR mammary cancer*[tiab] OR mammary carcinoma*[tiab]) AND (("Vitamin B 6"[Mesh] OR vitamin B6[tiab] OR pyridoxine[tiab] OR pyridoxal phosphate[tiab] OR pyridoxal 5'-phosphate[tiab] OR PLP[tiab]) OR ("Vitamin B 12"[Mesh] OR vitamin B12[tiab] OR cobalamin*[tiab]) OR ("Methionine"[Mesh] OR methionine[tiab])) AND (women[tiab] OR woman[tiab] OR female*[tiab] OR "Women"[Mesh])`
2. `(("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab]) AND (("Vitamin B 6"[Mesh] OR vitamin B6[tiab] OR pyridoxine[tiab] OR pyridoxal 5'-phosphate[tiab] OR PLP[tiab]) AND (serum[tiab] OR plasma[tiab] OR circulating[tiab] OR blood[tiab] OR dietary[tiab] OR intake[tiab] OR diet*[tiab]))) OR (("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab]) AND (("Vitamin B 12"[Mesh] OR vitamin B12[tiab] OR cobalamin*[tiab]) AND (serum[tiab] OR plasma[tiab] OR circulating[tiab] OR blood[tiab] OR dietary[tiab] OR intake[tiab] OR diet*[tiab]))) OR (("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab]) AND (("Methionine"[Mesh] OR methionine[tiab]) AND (dietary[tiab] OR intake[tiab] OR diet*[tiab])))`
3. `("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab]) AND ((("Vitamin B 6"[Mesh] OR vitamin B6[tiab] OR pyridoxine[tiab] OR pyridoxal 5'-phosphate[tiab] OR PLP[tiab]) OR ("Vitamin B 12"[Mesh] OR vitamin B12[tiab] OR cobalamin*[tiab]) OR ("Methionine"[Mesh] OR methionine[tiab])) AND (risk[tiab] OR relative risk[tiab] OR odds ratio[tiab] OR hazard ratio[tiab] OR incidence[tiab] OR association[tiab])) AND (women[tiab] OR woman[tiab] OR female*[tiab] OR premenopaus*[tiab] OR postmenopaus*[tiab] OR menopaus*[tiab])`
4. `(("Women"[Mesh] OR women[tiab] OR female*[tiab] OR premenopaus*[tiab] OR postmenopaus*[tiab]) AND ("Breast Neoplasms"[Mesh] OR breast cancer*[tiab] OR breast neoplasm*[tiab]) AND (("Vitamin B 6"[Mesh] OR vitamin B6[tiab] OR pyridoxine[tiab] OR pyridoxal 5'-phosphate[tiab] OR PLP[tiab] OR "Vitamin B 12"[Mesh] OR vitamin B12[tiab] OR cobalamin*[tiab] OR "Methionine"[Mesh] OR methionine[tiab])) AND (cohort[tiab] OR prospective[tiab] OR longitudinal[tiab] OR "Cohort Studies"[Mesh] OR "Prospective Studies"[Mesh] OR case-control[tiab] OR "Case-Control Studies"[Mesh])) NOT (animals[mh] NOT humans[mh])`
5. `((breast cancer*[tiab] OR breast neoplasm*[tiab]) AND ((lowest categor*[tiab] OR low level*[tiab] OR deficiency[tiab] OR deficient[tiab] OR quartile*[tiab] OR quintile*[tiab] OR tertile*[tiab]) AND ((serum PLP[tiab] OR plasma PLP[tiab] OR pyridoxal 5'-phosphate[tiab] OR vitamin B6 intake[tiab] OR dietary vitamin B6[tiab]) OR (serum vitamin B12[tiab] OR plasma vitamin B12[tiab] OR cobalamin[tiab] OR vitamin B12 intake[tiab] OR dietary vitamin B12[tiab]) OR (methionine intake[tiab] OR dietary methionine[tiab]))) AND (relative risk[tiab] OR odds ratio[tiab] OR hazard ratio[tiab] OR risk[tiab] OR association[tiab]) AND (women[tiab] OR premenopaus*[tiab] OR postmenopaus*[tiab]))`

The merged candidate pool contained 47 unique articles.

### Eligibility and Screening

ProtoMA generated and applied these criteria:

Inclusion criteria:

- Observational studies with original data, including prospective or retrospective cohort studies, case-control studies, or nested case-control studies, that evaluate breast cancer incidence/risk in women.
- Studies conducted in pre-menopausal and/or post-menopausal women that report serum pyridoxal 5'-phosphate (PLP), dietary vitamin B6 intake, serum vitamin B12 levels, dietary vitamin B12 intake, or dietary methionine intake as the exposure of interest.
- Studies that compare higher categories of exposure with the lowest category of serum PLP, dietary vitamin B6 intake, serum vitamin B12, dietary vitamin B12 intake, or dietary methionine intake, or provide effect estimates across exposure categories.
- Studies reporting breast cancer risk/incidence as an outcome with relative risk estimates or equivalent effect measures (e.g., odds ratio or hazard ratio) and corresponding confidence intervals or sufficient data to derive them.

Exclusion criteria:

- Studies not limited to women, or studies that do not separately report results for women or for pre-menopausal/post-menopausal subgroups when mixed populations are included.
- Studies that do not assess serum PLP, dietary vitamin B6, serum vitamin B12, dietary vitamin B12, or dietary methionine intake as the main exposure, or that focus only on supplements, treatment interventions, biomarkers unrelated to these exposures, or non-dietary/non-serum measures.
- Studies that report breast cancer mortality, prognosis, recurrence, or survival without reporting incident breast cancer risk.
- Reviews, meta-analyses, editorials, conference abstracts without sufficient data, case reports, ecological studies, cross-sectional studies, and animal or in vitro studies.

47 candidates were screened and 15 were retained.

### Statistical Analysis

### Statistical analysis
The primary quantitative synthesis was based on **odds ratios (ORs)** as the common effect measure. When studies reported risk estimates as ORs, these were extracted directly; relative risks or hazard ratios were considered sufficiently comparable to ORs for rare disease outcomes and were harmonized to a common log-effect scale where appropriate. For each study, the natural logarithm of the effect estimate and its standard error were derived from the published **95% confidence interval**.

The principal meta-analysis compared the **highest category** of vitamin-related exposure with the **lowest category** reported in each study. Pooled estimates were calculated using both a **random-effects model** and a **fixed-effect model**, with the random-effects model treated as the primary analysis because substantial between-study variability was anticipated across study designs, populations, menopausal status, and exposure assessment methods.

A total of **11 studies** contributed to the quantitative synthesis. Under the **random-effects model**, the pooled OR for breast cancer risk was **0.818** (**95% CI 0.705-0.949; p = 0.0080**), indicating an inverse association between higher exposure and breast cancer risk. For comparison, the **fixed-effect model** yielded a pooled OR of **0.855** (**95% CI 0.808-0.906; p < 0.0001**).

Between-study heterogeneity was assessed using **Cochran's Q**, **I^2**, and **tau-squared (tau^2)**. Heterogeneity was substantial: **Q = 57.51, p = 0.000**, **I^2 = 82.6%**, and **tau^2 = 0.0478**. The I^2 statistic was interpreted as the proportion of total variability attributable to between-study heterogeneity rather than sampling error. Given this level of heterogeneity, greater emphasis was placed on the random-effects summary estimate.

All pooled analyses were based on inverse-variance weighting. Statistical significance was assessed using two-sided p-values, and 95% confidence intervals were reported for all summary estimates. Quantitative synthesis was limited to studies with sufficiently comparable exposure contrasts and available effect estimates; studies lacking compatible data were retained in the qualitative review only.

## Results

### Study Selection

### Results of Search
The literature search identified **47 records** in total (**47 from local sources and 0 from PubMed**) after deduplication. All **47 records** underwent title and abstract screening, of which **32 were excluded** at the first screening stage. This left **15 full-text articles** for eligibility assessment. No studies were excluded at the full-text stage (**n = 0**), and **15 studies** met the inclusion criteria and were included in the systematic review. Thus, the review achieved complete inclusion of all studies assessed in full text.

Most frequent recorded exclusion reasons:

- Assesses vitamin status and homocysteine among existing breast cancer patients rather than incident breast cancer risk.: 1
- Reports survival among breast cancer survivors, not incident breast cancer risk.: 1
- Primary focus is MTHFR C677T polymorphism; nutrient intakes are modifiers rather than the main exposure of interest.: 1
- Meta-analysis, not an original observational study.: 1
- Systematic review and meta-analysis on vitamin E, not an original observational study of the specified exposures.: 1
- Exposure is dietary antioxidant index rather than serum PLP, dietary vitamin B6, serum vitamin B12, dietary vitamin B12, or dietary methionine.: 1
- Systematic review and meta-analysis, not an original observational study.: 1
- Study is not limited to breast cancer and does not clearly report breast cancer-specific results for the specified exposures in the abstract.: 1
- Primary focus is genetic polymorphisms and gene-nutrient interaction; vitamin B6 and B12 intakes are not the main exposure of interest.: 1
- Focuses on genetic polymorphisms and genomic stability in breast cancer patients rather than incident breast cancer risk.: 1

### Included Study Records

| Corpus ID | Year | Title |
|---:|---:|---|
| 62035 | 2008 | Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. |
| 62107 | 2012 | Prediagnostic plasma pyridoxal 5'-phosphate (vitamin b6) levels and invasive breast carcinoma risk: the multiethnic cohort. |
| 62036 | 2007 | Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. |
| 95982 | 2011 | Dietary intake of vitamin B(6) and risk of breast cancer in Taiwanese women. |
| 62006 | 2010 | Folate and other one-carbon metabolism-related nutrients and risk of postmenopausal breast cancer in the Cancer Prevention Study II Nutrition Cohort. |
| 441 | 2013 | Dietary intake of B vitamins and methionine and breast cancer risk. |
| 62108 | 2013 | Dietary intake of folate, B-vitamins and methionine and breast cancer risk among Hispanic and non-Hispanic white women. |
| 62037 | 2006 | Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women. |
| 437 | 2006 | Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women. |
| 440 | 2011 | Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. |
| 62104 | 2014 | Associations of dietary folate, Vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women. |
| 434 | 2001 | Dietary intake of selected micronutrients and breast-cancer risk. |
| 61997 | 2021 | Dietary Methyl-Group Donor Intake and Breast Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). |
| 435 | 2003 | Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. |
| 438 | 2008 | Choline metabolism and risk of breast cancer in a population-based study. |

### Study Characteristics

### Study Characteristics

A total of 15 studies comprising 674,518 participants were included. The studies were published between 2001 and 2021, with most reports appearing between 2006 and 2014; one record had no clearly reported publication year. Sample sizes varied substantially, from 731 participants in the smallest study to 318,686 in the largest, indicating marked variation in study scale, and one study did not provide a usable participant count in the extracted data. Geographically, the evidence base was dominated by studies from the United States (n=4), with additional studies from Taiwan, Australia, Mexico, France, China, Switzerland, and one multinational European study; for four studies, the country was not reported. Overall, this distribution suggests a predominantly high- and middle-income country evidence base, with limited representation from other regions.

There was considerable methodological heterogeneity across the included studies. Broadly, 7 studies used cohort or prospective cohort designs, while 8 used case-control approaches, including nested case-control and population-based case-control designs. This mix of longitudinal and retrospective observational designs is important when interpreting comparability across studies. Data quality from the enhanced extraction was generally strong: 14 studies were rated as high confidence and 1 as medium confidence. However, risk-of-bias judgments were less favorable, with 7 studies categorized as high risk and 8 as unclear risk overall. In addition, key bias domains such as random sequence generation, allocation concealment, and blinding were uniformly rated as unclear, reflecting either incomplete reporting or limited applicability of these domains to observational designs.

Notable heterogeneity was also evident in study-level reporting. The extracted dataset did not provide sufficiently consistent information on participant age, sex distribution, baseline condition severity, or on intervention characteristics such as dose, duration, and mode of delivery, preventing a detailed cross-study comparison of these features. Likewise, outcome measures were not reported in a standardized way in the extracted data, suggesting variability in how endpoints were defined and assessed across studies. Taken together, the included evidence spans diverse settings, populations, and observational designs, but differences in study methods and incomplete reporting of key clinical characteristics should be considered when interpreting the overall findings.

### Main Findings

## Results

### Primary outcome

The pooled analysis demonstrated an overall inverse association between higher exposure to vitamin B6, vitamin B12, and methionine-related measures and breast cancer risk in women, when the highest categories were compared with the lowest categories. Using a random-effects model across 11 studies, the pooled odds ratio (OR) was **0.818** (95% CI **0.705 to 0.949**; **p=0.008**). This indicates that women in the higher exposure categories had, on average, a lower risk of breast cancer than those in the lowest categories.

The fixed-effects model yielded a similar, though slightly more conservative, estimate (**OR 0.855**, 95% CI **0.808 to 0.906**; **p<0.001**), supporting the direction of the association. Because between-study heterogeneity was substantial, the random-effects estimate is the more appropriate summary measure.

### Direction and magnitude of effect

The magnitude of the pooled association suggests a **modest but potentially meaningful protective effect**. Specifically, the random-effects estimate corresponds to an approximately **18.2% relative reduction** in breast cancer risk among women with higher levels or intakes of the studied exposures compared with those in the lowest categories. Based on the fixed-effects model, this reduction was approximately **14.5%**.

Clinically, this effect size is not large, but it is consistent with a potentially relevant association at the population level, particularly given the widespread exposure to these nutrients through diet and circulation. However, the confidence interval indicates some uncertainty regarding the precise magnitude of benefit, with the true effect plausibly ranging from a small reduction to a more moderate reduction in risk.

### Consistency across studies

Despite the overall inverse association, consistency across studies was limited. Heterogeneity was **considerable** (**I²=82.6%**, Q=57.51, **p<0.001**; τ²=0.0478), indicating that much of the variability in study results was unlikely to be due to chance alone. This level of heterogeneity suggests that the strength of the association differed materially across studies.

Such inconsistency may reflect differences in exposure type and assessment method, including serum pyridoxal 5'-phosphate versus dietary vitamin B6 intake, serum versus dietary vitamin B12, and dietary methionine intake, as well as variation in menopausal status, baseline nutritional status, study design, confounder adjustment, and category definitions across studies. Accordingly, while the overall direction favored a protective association, the pooled estimate should be interpreted with appropriate caution.

### Notable individual study patterns

Although individual study-level weights and estimates are not provided in the summary data, the difference between the fixed-effects and random-effects pooled estimates was relatively small, suggesting that the most precise studies likely also pointed toward a modest inverse association rather than an effect in the opposite direction. At the same time, the high I² indicates that less precise studies or studies with different exposure definitions likely reported effect sizes ranging from null associations to stronger protective associations.

Thus, the overall result does not appear to be driven solely by a single extreme estimate in the opposite direction, but rather by a body of evidence showing a generally protective pattern with variable magnitude.

### Outliers and possible explanations

The substantial heterogeneity also implies the presence of outlying or divergent study results. While specific outlier studies cannot be identified from the summary statistics alone, the observed between-study dispersion suggests that some studies reported either little association or substantially stronger inverse associations than the pooled average. Potential explanations include differences in biomarker versus dietary measures, laboratory methods for serum assessment, residual confounding, variation in dietary patterns across populations, and biological differences between pre-menopausal and post-menopausal women.

Overall, the evidence supports an inverse association between higher vitamin B6, vitamin B12, and methionine exposure and breast cancer risk, but the strength of this association varied considerably across studies.

### Risk of Bias

### Risk of Bias

Across the 15 included studies, the overall risk-of-bias profile was unfavorable and dominated by poor reporting. After harmonizing labels, 7/15 studies were judged to be at high risk of bias and 8/15 at unclear risk; no study was judged overall low risk. At the domain level, concerns were universal: all 15 studies were rated as **unclear risk** for random sequence generation, allocation concealment, blinding of participants/personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. Thus, the most common bias concerns were not isolated to a single methodological feature but affected **every core RoB domain in all included studies (15/15 each)**. The consistent reason recorded across studies was that these domains were **not reported in the articles** (“No information available”), indicating that the main limitation was insufficient methodological transparency rather than explicitly documented flaws in one or two domains.

Because domain-level reporting was uniformly inadequate, meaningful patterning of RoB by study type could not be assessed reliably; in particular, differences between randomized and observational studies could not be examined from the available information. Nevertheless, the study-level pattern suggests a broadly weak evidence base: several studies were categorized overall as high risk (including studies from 2001, 2006, 2008, 2011, 2013, and 2014), while the remainder were unclear rather than low risk. Importantly, even the studies judged as “unclear” overall still had **unclear ratings in all six bias domains**, so they should not be interpreted as methodologically robust. Conversely, there were **no studies at clearly low risk** in any domain, meaning there is no subset of trials with well-documented randomization, concealment, blinding, attrition handling, or reporting practices to anchor confidence in the findings.

This RoB profile reduces confidence in the pooled estimate. Universal uncertainty around sequence generation and allocation concealment raises the possibility of selection bias; lack of reporting on participant/personnel and outcome-assessor blinding introduces potential performance and detection bias; and absent information on incomplete outcome data and selective reporting means attrition and reporting biases cannot be excluded. As a result, the pooled effect may be exaggerated, attenuated, or unstable, and should be interpreted cautiously. At the same time, the enhanced extraction pipeline indicated generally strong **data extraction quality** (14 studies high confidence, 1 medium, 0 low), suggesting that the RoB summary is likely reliable as an assessment of what was reported. However, high extraction confidence does not compensate for poor primary-study reporting. Overall, the certainty of conclusions drawn from this body of evidence is limited chiefly by the pervasive lack of methodological detail across all included studies.

## Discussion

## Discussion

This systematic review and meta-analysis suggests that higher exposure to one-carbon metabolism-related nutrients, considered collectively across vitamin B6, vitamin B12, and methionine measures, is associated with a modestly lower odds of breast cancer in women. Across 11 studies contributing to the pooled analysis, the random-effects summary estimate was 0.818 (95% CI 0.705 to 0.949; p=0.008), indicating an approximately 18% lower relative odds of breast cancer when comparing higher exposure categories with the lowest categories. The fixed-effect estimate was similar in direction but slightly attenuated (OR 0.855, 95% CI 0.808 to 0.906), which supports the overall consistency of the inverse association. From a clinical and public health perspective, this effect size is modest rather than large, but it is potentially meaningful given the high population burden of breast cancer and the modifiable nature of nutritional exposures. At the same time, the substantial between-study heterogeneity (I2=82.6%, Q p<0.001) requires a cautious interpretation and argues against treating this pooled estimate as a precise universal effect.

The findings are broadly compatible with the wider literature linking nutritional and metabolic factors to cancer risk, although direct comparison with the prior meta-analyses provided here is necessarily indirect because those reviews addressed different populations, exposures, and outcomes. Unlike the bariatric surgery review, which found no strong evidence that post-surgical dietary composition was associated with long-term weight outcomes, the present review identified a statistically significant association between nutrient exposure and breast cancer risk. That contrast likely reflects both biological differences between the outcomes studied and the fact that micronutrient status may have a more specific mechanistic relevance to carcinogenesis than broad macronutrient patterns do to post-bariatric weight trajectories. Our findings are also conceptually aligned with the gastric cancer meta-analysis showing that adverse metabolic status, reflected by poor glycaemic control, was associated with higher cancer risk. Together, these reviews support the broader view that systemic metabolic and nutritional states may influence cancer development, although the direction and magnitude of effect depend heavily on the exposure and disease context. By contrast, the preterm infant vitamin D review demonstrated clear short-term biomarker and growth effects under supplementation, a level of intervention evidence that is not available in the present literature; accordingly, our conclusions should remain more conservative because they are based predominantly on observational comparisons rather than randomized exposure assignment.

Biological plausibility for the observed association is reasonable. Vitamin B6, particularly in its active form pyridoxal 5'-phosphate (PLP), functions as a cofactor in one-carbon metabolism, nucleotide synthesis, methylation reactions, and pathways related to oxidative stress and inflammation. Vitamin B12 is also central to methyl-group transfer and DNA synthesis, and methionine is a key methyl donor precursor through the methionine cycle. In principle, inadequate status of these nutrients could contribute to impaired DNA synthesis and repair, aberrant DNA methylation, genomic instability, or altered cell proliferation, all of which are relevant to breast carcinogenesis. Serum PLP may be especially informative because it captures internal nutrient status more directly than dietary intake alone, which is vulnerable to recall error and variation in absorption and metabolism. However, plausibility should not be conflated with proof. One-carbon metabolism is complex, interacts with folate and other B vitamins, and may operate differently across menopausal states, tumor subtypes, alcohol intake levels, and background dietary patterns. It therefore remains possible that the pooled association reflects a mixture of true biological effects and correlated healthy-behavior patterns.

The most important challenge in interpreting the results is the high heterogeneity. Several sources are likely. First, the exposure definition was necessarily broad: this review grouped serum PLP, dietary vitamin B6, serum vitamin B12, dietary vitamin B12, and dietary methionine intake under a shared biological framework, but these are not interchangeable measures. Biomarkers and dietary estimates capture different constructs, and diet-based categories are especially sensitive to measurement error. Second, the included populations likely varied by menopausal status, geography, baseline nutritional adequacy, supplement use, alcohol consumption, and fortification practices, all of which could modify associations. Third, study design and analytic choices probably differed, including case-control versus cohort structures, category cut-points, confounder adjustment sets, and whether estimates were reported for total breast cancer or specific subgroups. Fourth, some studies appear to have reported only subgroup-specific or category-based adjusted estimates without raw event counts, limiting harmonization and potentially increasing dependence on reported models. These factors make it plausible that the summary effect represents an average across genuinely different underlying associations rather than a single common effect.

This review also has notable strengths. It includes 15 studies overall, with 11 contributing to quantitative synthesis, and the data quality profile was generally strong: 14 studies were assessed as high quality and 1 as medium quality, with none classified as low quality. A further strength is the use of enhanced extraction methods, which allowed capture of effect estimates even when raw 2x2 data were unavailable, thereby preserving information that would often be lost in conventional extraction workflows. That matters in a literature where many observational studies report adjusted odds ratios from exposure categories rather than reconstructable raw tables. In addition, by considering both biomarker-based and dietary measures of vitamin B6 and vitamin B12, alongside methionine intake, the review addresses a biologically coherent pathway rather than a single isolated nutrient. This broader framing helps situate the findings within one-carbon metabolism and may be more informative than examining each exposure in isolation when the evidence base for individual contrasts is sparse.

Several limitations should temper the conclusions. First, the evidence base is observational, so residual confounding, reverse causation, and selective reporting cannot be excluded. Second, substantial heterogeneity reduces confidence in the exact pooled magnitude. Third, although most studies were rated high quality overall, the extracted records show recurring reporting limitations, including incomplete bibliographic metadata, absent raw event counts, missing group-specific sample sizes, and in some cases only subgroup-level adjusted estimates. These issues do not invalidate the studies, but they constrain reproducibility, limit exploration of dose-response patterns, and may affect comparability across studies. Fourth, the pooled analysis appears to combine related but distinct exposures; while biologically defensible, this may also obscure nutrient-specific effects. Fifth, generalizability may be limited if the included studies were concentrated in particular settings or dietary backgrounds, and the extent to which findings apply equally to pre-menopausal and post-menopausal women remains uncertain. On balance, the current evidence does not justify a strong clinical recommendation to increase vitamin B6, vitamin B12, or methionine exposure specifically for breast cancer prevention in the absence of deficiency or another indication. The more defensible implication is that adequate nutritional status within the one-carbon metabolism pathway may be relevant to breast cancer risk and deserves attention in women’s health research and prevention strategies. Future studies should prioritize prospective designs, standardized exposure definitions, repeated biomarker assessment, careful control for confounding dietary and lifestyle factors, and stratified analyses by menopausal status, tumor subtype, and folate/alcohol context. Nutrient-specific meta-analyses and dose-response evaluations would also help determine whether the observed inverse association is driven primarily by serum PLP, vitamin B12 status, methionine intake, or their combination.

## Conclusion

In this meta-analysis of 15 studies, higher exposure to one-carbon metabolism nutrients, specifically vitamin B6, vitamin B12, and methionine, was associated with a lower breast cancer risk than the lowest exposure categories, with a pooled random-effects OR of 0.818 (95% CI 0.705-0.949; p=0.008). Clinically, this corresponds to about an 18% relative reduction in risk, which is potentially meaningful at the population level, particularly for women across premenopausal and postmenopausal groups, but it is not large enough on its own to support these nutrients as a stand-alone preventive strategy. These findings support a qualified recommendation to maintain adequate vitamin B6 and B12 status and dietary methionine intake as part of an overall balanced dietary pattern rather than using isolated nutrient exposure as a primary breast cancer prevention approach. The main caveat is the substantial between-study heterogeneity (I2=82.6%), which limits confidence in a uniform effect across populations, exposure measures, and study designs.

## Final Included Studies

- Corpus ID: 62035 | Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women.
- Corpus ID: 62107 | Prediagnostic plasma pyridoxal 5'-phosphate (vitamin b6) levels and invasive breast carcinoma risk: the multiethnic cohort.
- Corpus ID: 62036 | Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women.
- Corpus ID: 95982 | Dietary intake of vitamin B(6) and risk of breast cancer in Taiwanese women.
- Corpus ID: 62006 | Folate and other one-carbon metabolism-related nutrients and risk of postmenopausal breast cancer in the Cancer Prevention Study II Nutrition Cohort.
- Corpus ID: 441 | Dietary intake of B vitamins and methionine and breast cancer risk.
- Corpus ID: 62108 | Dietary intake of folate, B-vitamins and methionine and breast cancer risk among Hispanic and non-Hispanic white women.
- Corpus ID: 62037 | Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women.
- Corpus ID: 437 | Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women.
- Corpus ID: 440 | Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women.
- Corpus ID: 62104 | Associations of dietary folate, Vitamins B6 and B12 and methionine intake with risk of breast cancer among African American and European American women.
- Corpus ID: 434 | Dietary intake of selected micronutrients and breast-cancer risk.
- Corpus ID: 61997 | Dietary Methyl-Group Donor Intake and Breast Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).
- Corpus ID: 435 | Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort.
- Corpus ID: 438 | Choline metabolism and risk of breast cancer in a population-based study.
